{"id":"NCT06097273","sponsor":"ModernaTX, Inc.","briefTitle":"A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age","officialTitle":"A Phase 3, Randomized, Observer-Blind, Active-Control Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2023-10-19","primaryCompletion":"2024-05-28","completion":"2024-05-28","firstPosted":"2023-10-24","resultsPosted":"2025-06-13","lastUpdate":"2025-07-01"},"enrollment":8061,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["SARS-CoV-2","Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"mRNA-1083","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]},{"type":"BIOLOGICAL","name":"Influenza Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"COVID-19 Vaccine","otherNames":[]}],"arms":[{"label":"Cohort A1: mRNA-1083 and Placebo","type":"EXPERIMENTAL"},{"label":"Cohort A2: Influenza Vaccine and COVID-19 Vaccine","type":"ACTIVE_COMPARATOR"},{"label":"Cohort B1: mRNA-1083 and Placebo","type":"EXPERIMENTAL"},{"label":"Cohort B2: Influenza Vaccine and COVID-19 Vaccine","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1083 as compared with active control, co-administered licensed influenza and severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) vaccines, in 2 independent age-group sub-study cohorts, healthy adults 65 years and older (Cohort A) and healthy adults 50 to \\<65 years of age (Cohort B).","primaryOutcome":{"measure":"Geometric Mean (GM) Level of Antibodies for Influenza, as Measured by Hemagglutination Inhibition (HAI) Assay","timeFrame":"Day 29","effectByArm":[{"arm":"Cohort A1: mRNA-1083 and Placebo","deltaMin":120.5,"sd":null},{"arm":"Cohort A2: Influenza Vaccine and COVID-19 Vaccine","deltaMin":104.3,"sd":null},{"arm":"Cohort B1: mRNA-1083 and Placebo","deltaMin":137.7,"sd":null},{"arm":"Cohort B2: Influenza Vaccine and COVID-19 Vaccine","deltaMin":97.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":146,"countries":["United States"]},"refs":{"pmids":["40332892","39481241"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":71,"n":2011},"commonTop":[]}}